A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Summary

The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer

Eligibility

Inclusion Criteria:

* Signed written informed consent;
* Eastern Cooperative Oncology Group Performance Status of 0 or 1
* Untreated pathologically confirmed colon adenocarcinoma
* Radiographic assessment showed a resectable stage IIB-III based on AJCC Stage VIII (cT4 or cN+ only).
* Has a tumor demonstrating the presence of MSI-H/ dMMR
* Adequate organ function as described in the protocol

Exclusion Criteria:

* Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc
* Has distant metastatic disease.
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has know history of, or any evidence of interstitial lung disease;
* Has an active infection requiring systemic therapy

Conditions2

Interventions2

Related trials

• A Phase II Study of CRT Combined With QL1706 in ESCC Patients — Tianjin Medical University Cancer Institute and Hospital
• A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors — Qilu Pharmaceutical Co., Ltd.
• First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients — Fudan University
• Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma — Nanjing Tianyinshan Hospital
• Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors — Peking Union Medical College Hospital
• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer — Wenjin Yin
• Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. — Sun Yat-Sen University Cancer Center

Browse More Trials